MAb Affinity Maturation == Spiked oligonucleotide mutagenesis, light chain shuffling and error prone PCR-mediated random mutagenesis were used for affinity maturation of scFv 71E4, 71F4, and CR1. significant implications for existing countermeasures and potential vulnerabilities. Keywords:monoclonal antibodies, botulinum neurotoxin, botulism,Clostridium botulinum, botulinum neurotoxin HA, BoNT/HA == 1. Introduction == Botulinum neurotoxins (BoNTs), the most poisonous substances known [1], consist of three functional domains [2]: a binding domain name (HC), translocation domain name (HN) and catalytic domain name (LC). BoNTs exist as seven accepted serotypes (AG), defined immunologically by the inability of polyclonal antibody that neutralizes one serotype to neutralize other serotypes [3]. Toxin serotypes A, B, E, and F can be further subdivided into subtypes or genetic variants (A1A8, F1-9) based on sequence and immunologic differences [4]. Additional toxins with structural homology to BoNT have also been recently identified and include BoNT/X from a Clostridial species and eBoNT/J [5,6] from an Enterococcal species. In 2014, a novel neurotoxin was reported that was produced by the bivalentClostridium botulinumstrain IBCA10-7060, which also produced BoNT/B2 [7,8]. The novel BoNT appeared to be chimeric with a HCmost homologous to BoNT/A1 (~84%) and an HNand LC most homologous to BoNT/F5 Lansoprazole sodium (~64% and ~81% respectively) [8] (Physique S1). In the initial report, the novel neurotoxin was considered a new serotype, BoNT/H, based on failure of neutralization using the standard mouse bioassay [7] and also using a research antitoxin at antitoxin:toxin ratios as high as 595:1 [7]. Subsequent work demonstrated that Lansoprazole sodium this novel BoNT could be neutralized by a combination of anti-A and anti-B research antitoxin at ratios ranging from 20:1 to 200:1 [9,10]. Based on this neutralization and the mosaic structure of the novel toxin with its homology to parts of BoNT/A and BoNT/F5, these authors Rabbit Polyclonal to PARP4 and others termed the novel toxin BoNT/FA [10,11]. However, the novel BoNT was not neutralized by anti-BoNT/F antitoxin [9,10] and was bound by only one of six anti-BoNT/F monoclonal antibodies (mAbs) and with an affinity more than 8000-fold lower than the affinity for BoNT/F1 (KD= 9.1 pM vs. ~75 nM) [12]. Based on these findings, the novel BoNT has also been termed BoNT/HA [13,14]. We sought to better define the immunologic nature of the novel BoNT by generating a panel of mAbs against the LC-HNportion of the novel toxin and determining their ability to bind other BoNT serotypes. The results indicate that immunologically, the novel BoNT is usually BoNT/HA, which has significant implications for existing countermeasures and potential vulnerabilities. == 2. Results == Since the novel BoNT has been termed BoNT/H, BoNT/FA, BoNT/HA and the novel neurotoxin produced by strain IBCA10-7060, for clarity and brevity we will refer to the novel BoNT throughout the results section by the first name used to Lansoprazole sodium describe it, BoNT/H [7]. In the discussion and conclusion, we will use the name that is supported by the studies performed, BoNT/HA. == 2.1. BoNT/H LC-HNFragment Expression and Mouse Immunization == To focus the immune response around the portion of the novel BoNT not homologous to BoNT/A, the BoNT/H LC-HNgene encoding amino acids 1859 was cloned into plasmid pET28b, expressed fromEscherichia. coliand purified by IMAC (Physique S2A). The recombinant BoNT/H LC-HNwas bound by the BoNT/H HNmAb 6F5.4 [12] and by anti-His tag IgG by ELISA (Determine S2B). The BoNT/H LC (amino acids 1444) was produced similarly and was of the expected size by SDS-PAGE (Physique S2A). Mice were immunized with BoNT/H LC-HNand serum harvested at six weeks after the initial immunization. Lansoprazole sodium Immune serum.